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Abstract
Background: Clear cell renal cell carcinoma (ccRCC) is among the most common human malignancies.
Methods: In order to provide better understanding of the molecular biology of ccRCC and to identify potential
diagnostic/prognostic biomarker and therapeutic targets, we utilized a microarray to profile mRNA expression of
corresponding normal and malignant renal tissues. Real-time PCR, Western Blot and immunohistochemistry were
applied to study the expression of candidate biomarkers. ccRCC cell lines were treated with sertraline to inhibit the
dopamine transporter SLC6A3.
Results: Differential expression of fourteen mRNAs, yet not studied in ccRCC in depth, was confirmed using qPCR
(upregulation: SLC6A3, NPTX2, TNFAIP6, NDUFA4L2, ENPP3, FABP6, SPINK13; downregulation: FXYD4, SLC12A1,
KNG1, NPHS2, SLC13A3, GCGR, PLG). Up-/downregulation was also confirmed for FXYD4, KNG1, NPTX2 and SLC12A1
by Western Blot on the protein level. In contrast to the mRNA expression, protein expression of the dopamine
transporter SLC6A3 was lower in ccRCC compared to normal renal tissue. Immunohistochemistry indicated that this
decrease was due to higher concentrations of SLC6A3 in the proximal tubules. Immunohistochemical analyses
further demonstrated that high SLC6A3 expression in ccRCC tissue was correlated with a shorter period of
recurrence-free survival following surgery. Treatment of ccRCC cells with the SLC6A3 inhibitor sertraline induced
dose-dependent cell-death.
Conclusion: Our study identified several novel biomarkers with diagnostic potential and further investigations on
sertraline as therapeutic agent in ccRCC patients are warranted.
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Background
Renal cell carcinoma (RCC) is one of the most common
malignancies in developed countries: there are 115,200
new cases and 49,000 death estimated for 2012 in
Europe [1]; and the incidence of RCC is increasing in
the USA, especially in young patients and high-grade
disease [2]. The widespread use of abdominal ultrason-
ography for check-up or clarification of non-specific
symptoms led to an increased detection of small-sized
renal tumors. Small renal tumors are non-malignant in
up to one third, but imaging does often not allow precise
identification of non-malignant tumors, and thus poten-
tial harmful overtherapy occurs often. While the resec-
tion of small RCC is usually curative, the prognosis of
metastatic RCC is poor: surgery (cytoreductive nephrec-
tomy, metastasectomy [3]) and targeted therapy [4]
improved patients survival, but eventually most patients
succumb to the disease.
From a clinical point of view, a non-invasive bio-
marker could help to reduce overtherapy in case of small
renal tumors, and furthermore, could be helpful for
clinical monitoring during medical tumor therapy.
Despite extensive research during the past years, there is
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powerful tool to identify dysregulated genes in cancer
tissue. We therefore applied a microarray to identify
RNAs dysregulated in RCC patients. Genes showing
differential expression were then validated using qPCR
and Western Blot.Results
Microarray: screening for aberrantly expressed mRNAs
The expression of 34,144 mRNA transcripts was deter-
mined using a microarray in 15 corresponding tumor and
normal renal tissue samples. We observed differential
expression, defined as log2-fold expression difference >2,
in 1064 (3.1 %) transcripts: 368 mRNA transcripts were
upregulated and 696 were downregulated in ccRCC
samples. A hierarchical cluster analysis based on centered
Pearson correlation coefficient was performed to deter-
mine different expression profiles in ccRCC and normal
tissue. As shown in Fig. 1, the mRNA expression profile
allowed to separate cancerous and normal tissue samples
accurately. The most differentially expressed mRNAs
in ccRCC and normal renal tissue are listed in
Table 1. The Reactome database [5] was used to per-
form pathway analyses for these genes: affected path-
ways (FDR <0.05, p < 0.005) included glycolysis; glucose
transport and metabolism; regulation of IGF transport;
cellular response to hypoxia; regulation of HIF; transmem-
brane transport; lipid digestion, mobilization and trans-
port. We further validated gene expression using 19
datasets comparing ccRCC and normal renal tissue
from the NextBio tool [6]; as shown in Additional
file 1 Figure S1, the dysregulation of these genes was
also observed in former gene expression profiling
studies.Real-Time PCR: validation of expression profiling
We next investigated the expression of 14 dysregu-
lated mRNAs - not investigated by other researchers
before - with an independent validation cohort of ccRCC
(n = 52) and normal (n = 51) renal tissue samples using
qPCR. As expected, we observed significant (all p < 0.001)
upregulation of SLC6A3 (fold-change expression: mean
230-fold), NPTX2 (188-fold), TNFAIP6 (100-fold), NDU-
FA4L2 (78-fold), ENPP3 (42-fold), FABP6 (39-fold), and
SPINK13 (26-fold) in ccRCC tissue. We also confirmed
downregulation (all p < 0.001) of FXYD4 (mean 2371-
fold), SLC12A1 (912-fold), KNG1 (758-fold), NPHS2
(407-fold), SLC13A3 (62fold), GCGR (27-fold), PLG (21-
fold) in ccRCC tissue compared to normal renal tissue.
Up- or downregulation allowed accurately identification
of malignancy based on molecular signature: especially
the loss of SLC12A1 was useful for diagnostic purposes
as all malignant and benign samples were classifiedcorrectly (ROC analysis: sensitivity and specificity
100 %, area under the curve 1.0). See Table 2 and Fig. 2.
We also determined whether mRNA expression levels
in RCC patients were correlated with clinicopathological
parameters. After correction for multiple hypothesis
testing (Benjamini-Hochberg-procedure), we did not
observe a significant association of any investigated
mRNA and pT-stage, metastasis nor grading (all p > 0.03).
However, there was a trend towards increased SLC6A3
levels in patients with metastases (p = 0.046). The mRNA
levels were also not correlated with RCC recurrence nor
survival, as determined using Cox regression analysis (all
p > 0.1). We also retrieved the TCGA project data [7] via
the cBio Cancer Genomics Portal [8]; SLC6A3 mRNA
expression levels (RNA Seq V2 RSEM) were overex-
pressed in a subgroup of 5 % of the ccRCC samples and
patients with high SLC6A3 expression in the tumor tissue
had a shorter period of overall survival (median
period of survival 40 vs. 75 months); See Additional
file 1: Figure S2.
Western Blot: validation on protein level
The expression of FXYD4, SLC6A3, SLC12A1, NPTX2,
NDUF4AL2 and KNG1 was determined in homogenized
renal tissue (eight corresponding normal renal and
ccRCC tissues) using Western Blot analyses. As shown
in Fig. 3, NPTX2 expression was distinctly increased in
tumor tissues. FXYD4, KNG1 (full length and the light
chain) and SLC12A1 expression was decreased in ccRCC
tissues. In contradiction to the mRNA expression,
SLC6A3 and NDUF4AL2 levels were lower in tumor
compared to normal renal tissues.
Immunohistochemistry: expression of SLC6A3 in primary
RCC
In order to investigate the expression of SLC6A3 more
detailed and in an enlarged cohort, we performed immu-
nohistochemistry on a tissue microarray with 134 ccRCC
and 21 normal renal tissues. SLC6A3 was strongly
expressed at the membrane of tumor and normal cells,
but also in the cytoplasm (see Fig. 4). In contrast to the
mRNA expression, but in correspondence to the Western
Blot analysis, SLC6A3 expression was significantly de-
creased in ccRCC tissue compared to normal renal tissue.
SLC6A3 expression was low in the loop of Henle
(both p < 0.0001), but high in the proximal tubules
(p < 0.001) compared to ccRCC. Expression in ccRCC
tissue and distal tubules was similar (p = 0.191). See
Fig. 4.
SLC6A3 protein expression was increased in patients
with distant metastasis (p = 0.002), but not correlated to
AJCC stage, pT-stage, lymph node metastasis nor grading
(all p > 0.1). Univariate Cox regression analysis indicated
that an increased SLC6A3 immunostaining was correlated
Fig. 1 The expression of 34,144 mRNA transcripts was determined using a microarray in 15 corresponding tumor (red bar below heatmap) and
normal (green) renal tissue samples. The mRNA expression profile allowed accurate discrimination of normal and clear cell renal carcinoma tissue;
the heatmap demonstrates clustering of tissue samples according the expression of the 25 most up-/downregulated genes
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ratio 6.7, 95 % confidence interval 3.4-18322.9); however,
the predictive value was lost in a multivariate model which
included pT-stage, lymph node/distant metastasis and
grading (p = 0.365). The Kaplan-Meier estimate for the
impact of SLC6A3 expression (stratified according the
mean expression level in ccRCC) on progression-free
survival is shown in Fig. 4.
Determination of circulating SLC6A3 levels
The concentration of circulating SLC6A3 was de-
termined using an ELISA assay. SLC6A3 was detected
in serum of one patient with metastatic ccRCC (mul-
tiple bilateral lung metastases) at a concentration of
0.267 ng/ml. All remaining control subjects and
ccRCC patients had SLC6A3 levels below the limit of
detection (data not shown).Treatment of RCC cell lines with the SLC6A3 inhibitor
sertraline
We first determined SLC6A3 expression in ACHN,
A498, Caki-1, Caki-2 and 769-P RCC cell lines; based on
the SLC6A3 expression levels in the cell lines, we ex-
cluded ACHN, Caki-2 and 769-P from further analyses.
Caki-1 and A498 cells were treated with the SLC6A3
inhibitor sertraline at different concentrations. Sertraline
treatment resulted in a dose-dependent decrease of
cellular proliferation with significant decrease at 25 μM
and 50 μM doses. See Fig. 5.
Discussion
In order to identify novel biomarkers for ccRCC, we
investigated the mRNA expression profile in ccRCC
using a microarray, and identified 1064 differentially
expressed mRNA transcripts corresponding to 3 % of
Table 1 Summary of 25 most differentially expressed RNAs in clear cell renal cell carcinoma and normal tissue identified using
microarray analysis
Downregulated in cancer Upregulated in cancer
Gene Name Ensembl ID Log2 fold-change Gene Name Ensembl ID Log2 fold-change
AQP2 ENST00000199280 −10.63 CA9 ENST00000544074 7.34
UMOD ENST00000199280 −9.94 NDUFA4L2 ENST00000555173 6.63
SLC12A1 ENST00000380993 −9.15 FABP7 ENST00000368444 6.09
KNG1 ENST00000432028 −8.69 LOC100131551 ENST00000414120 6.00
TMEM213 ENST00000442682 −8.56 NPTX2 ENST00000265634 5.98
CALB1 ENST00000469032 −8.54 ANGPTL4 ENST00000301455 5.92
ATP6V0A4 ENST00000310018 −8.13 CDCA2 ENST00000435898 5.61
FXYD4 ENST00000476166 −7.99 LOC100129597 uncharacterized 5.59
FABP1 ENST00000295834 −7.79 FABP6 ENST00000523955 5.49
ALDOB ENST00000374855 −7.68 KISS1R ENST00000234371 5.45
KLK1 ENST00000448701 −7.31 TNFAIP6 ENST00000460812 5.28
SLC13A3 ENST00000279027 −7.12 HILPDA ENST00000466473 5.24
GCGR ENST00000400723 −6.85 C10orf99 ENST00000472542 4.72
ATP6V1G3 ENST00000489986 −6.83 SLC6A3 ENST00000270349 4.59
MT1H ENST00000332374 −6.75 COL23A1 ENST00000390654 4.59
RHCG ENST00000536247 −6.70 SPINK13 ENST00000511106 4.58
NPHS2 ENST00000367615 −6.54 C3 ENST00000463520 4.47
PLG ENST00000461414 −6.41 EGLN3 ENSG00000129521 4.44
SOST ENST00000301691 −6.40 CYP2J2 ENST00000371204 4.40
FLJ45983 uncharacterized −6.37 ENPP3 ENST00000358229 4.26
LHX1 ENST00000254457 −6.35 CD70 ENST00000245903 4.21
ALB ENST00000430202 −6.35 NNMT ENST00000299964 4.19
MT1G ENST00000379811 −6.35 SLC17A4 ENST00000377905 4.15
AFM ENST00000226355 −6.35 ANGPT2 ENST00000415216 4.10
SERPINA5 ENST00000537685 −6.32 HK2 ENST00000290573 4.08
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mRNA expression profiling studies in RCC patients, the
expression profiling allowed a distinction of ccRCC and
normal tissue accurately. The validity of the method was
further confirmed by quantitative PCR experiments: 14
mRNA - so far not investigated by others - were quanti-
fied in a larger cohort (52 ccRCC and 51 normal renal
tissues). Several other expression profiling [9–12] studies
also observed deregulation of these genes. Finally, we
confirmed the dysregulation of selected genes on the
protein level.
The dopamine transporter SLC6A3 (solute carrier fam-
ily 6 member 3, also termed DAT1) regulates dopamine
concentrations in the brain and expression changes are as-
sociated with Parkinson’s syndrome and attention-deficit/
hyperactivity disorder. However, the function of this trans-
membrane protein in the kidney and in carcinogenesis is
unknown. We observed a distinct increase of SLC6A3
mRNA (>200-fold) in ccRCC tissue compared to thenormal parenchyma indicating a role as tumor suppressor
gene. Surprisingly, protein levels were increased in the
normal renal tissue as measured using Western Blot. It
should be noted that approximately 40 % of the genes
have differential protein/mRNA levels, most probably due
to various levels of regulation during protein synthesis,
e.g. posttranscriptional, translational, or posttranslational
regulation [13, 14]. Notably, genes involved in mRNA
processing pathways (release of introns, 3’end processing,
mRNA export) are altered in ccRCC [15]. The more
detailed histological analysis demonstrated that especially
the proximal tubules expressed SLC6A3 at high levels,
whereas its levels were moderate in the tumor. Interest-
ingly, SLC6A3 expression was correlated with the time to
progression, as shown in the Kaplan Meier diagram.
Notably, the multivariate Cox regression analysis failed to
confirm the prognostic value, but the small size of the
cohort (n = 88) limited the statistical power. Of interest,
high SLC6A3 mRNA levels were predictive for shorter
Table 2 Expression differences of selected mRNA in the validation cohort identified using qPCR
mRNA fold change
(mean)
cancer normal ROC analysis area
under the curvemean median mean median
SLC6A3 230 379.006 335.639 1.645 0.810 0.955 (0.906-1.000)
NPTX2 188 246.544 107.117 1.314 0.595 0.993 (0.982-1.000)
TNFAIP6 100 170.493 60.204 1.701 0.944 0.980 (0.947-1.000)
NDUFA4L2 78 104.866 78.748 1.337 0.861 0.996 (0.989-1.000)
ENPP3 42 58.365 44.022 1.382 1.049 0.977 (0.939-1.000)
FABP6 39 49.888 11.631 1.279 0.948 0.677 (0.555-0.800)
SPINK13 26 51.221 20.516 1.948 0.939 0.894 (0.831-0.957)
FXYD4 −2371 0.001 0.000 2.371 1.179 0.998 (0.994-1.000)
SLC12A1 −912 0.002 0.000 1.596 1.352 1.000 (1.000-1.000)
KNG1 −758 0.002 0.000 1.602 1.259 1.000 (0.998-1.000)
NPHS2 −407 0.005 0.000 1.986 1.944 0.970 (0.936-1.000)
SLC13A3 −62 0.030 0.004 2.039 1.836 0.970 (0.943-0.997)
GCGR −27 0.047 0.000 1.291 1.195 0.983 (0.951-1.000)
PLG −21 0.113 0.006 2.406 1.401 0.927 (0.880-0.975)
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Seyednasrollah et al. suggest that solute carrier genes are
highly expressed in ccRCC and have an impact on ccRCC
patients outcome [16]. We also treated RCC cell lines with
sertraline, an inhibitor of the SLC6A3 protein, and
observed a dose-dependent, significant decrease of cell
proliferation. It was earlier shown that sertraline inducesFig. 2 The expression of 14 target mRNAs in renal cell carcinoma (red bars
real-time PCR; the expression levels were normalized using ACTB and TBP a
TFAIP6, NDUFA4L2, ENPP3, FABP6 and SPINK13 mRNA in renal cell carcinom
GCGR and PLG mRNA levels were downregulated (all p < 0.001)apoptosis in HepG2 hepatoma cells as a result of the acti-
vation of the TNF-MAP4K4-JNK cascade pathway [17].
Thus, sertraline - often used as antidepressant and pain
drug in palliative care settings in cancer patients - could
be a potential therapeutic agent in metastatic ccRCC. It
should be noted that sertraline, despite of being the most
potent antidepressant at the dopamine transporter, also) and normal renal (green bars) tissue was validated using quantitative
s reference genes. Significant overexpression of SLC6A3, NPTX2,
a was confirmed, whereas FXYD4, SLC12A1, KNG1, NPHS2, SLC13A3,
Fig. 3 Western blot experiments were performed to determine the
protein expression in eight corresponding normal (N) and clear cell
renal cell carcinoma (T) tissue. NPTX2 was increased in tumor tissue,
whereas FXYD4, KNG1, SLC12A1 and SLC6A3 were decreased in
tumors. NDUF4AL2 levels were similar, but the bands were of
different size in tumor and normal samples
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[18]. The SLC6A3 protein can be visualized in SPECT
and PET using radiolabeled ligands [19], it may be
speculated that SLC6A3 could be used to identify
metastases from ccRCC.Fig. 4 a SLC6A3 expression was determined using immunohistochemistry
immunohistochemical staining in ccRCC and normal renal tissue is shown.
expression in renal tissues: Nuclear, cytoplasmic and especially luminal-mem
whereas it was moderate in the distal tubules (DT) and clear cell renal cell
Henle (LoH). c SLC6A3 expression in tumor cells was predictive for progres
patients with SLC6A3 levels above the mean as shown in the Kaplan MeierThe relevance of NPTX2 (neuronal pentraxin 2)
expression in ccRCC was reported during later stages of
our experiments: van Roemeling et al. [20] also observed
upregulation of NPTX2 primary tumors and metastases.
Re-evaluation of the TCGA dataset by Seyednasrollah
et al. also revealed NPTX2 (among many other genes) as
predictive for poor outcome, but an internal validation
cohort failed to reproduce the prognostic role of NPTX2
[16]. It was shown that cell viability and cell migration
were promoted by interaction with the AMPA receptor
resulting in an influx of calcium into cancer cells. As
NPTX2 expression was functionally characterized
earlier, we did not perform knockdown experiments.
Notably, we did not notice a correlation of NPTX2
expression and clinical-pathological parameters, whereas
van Roemeling et al. suggested an increase of NPTX2 in
more advanced ccRCC [20]. In pancreatic cancer, NPTX2
expression is silenced by DNA hypermethylation [21].
Finally, we observed downregulation of FXYD4m
KNG1 and SLC12A1 in ccRCC tissue. FXYD4 (FXYD
containing ion transport regulator 4) modulates the Na-
K-ATPase [22]. FYXD4 has not been implicated in
human carcinogenesis so far. SLC12A1 (solute carrier
family 12 member 1) is a kidney specific sodium-
potassium-chloride co-transporter; it plays a key role inin renal tissues; a representative image showing SLC6A3
b The Boxplot diagram demonstrates the distribution of SLC6A3
branous SLC6A3 expression was high in proximal tubules (PT),
carcinoma tissue (ccRCC); it was only weakly expressed in the loop of
sion-free survival: the period of progression-free survival was shorter in
estimates
Fig. 5 Caki-1 (a) and A-498 (b) cells were treated with the SLC6A3 inhibitor sertraline at 12.5 μM, 25 μM and 50 μM; cell proliferation decreased in
a dose-dependent manner
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was also noticed by Liu et al. in ccRCC, and its expres-
sion levels were negatively correlated with miR-21
expression [23]. A pathogenic role in cancer was further
reported in ovarian cancer cell lines, which exhibited
increased SLC12A1 expression levels [24]. KNG1 (kinin-
ogen 1) plays an important role in blood coagulation,
but is also observed in renal tissue where it acts proin-
flammatory via the production of eNOS, NO, cGMP and
prostacyclin [25]. Blockage of KNG1 binding to endothe-
lial cells inhibited angiogenesis in a colon cancer mouse
model [26]. Increased KNG1 levels were detected in sera
of patients with hepatocellular carcinoma [27].
It should be noted that the composition of our study
cohorts was probably unsuited to identify genes with
prognostic impact: the microarray experiment included
only one patient with metastatic ccRCC; locally ad-
vanced RCC (pT3) was observed in 60 % of patients but
most patients had low grade ccRCC (G3 13 %). Also, the
PCR and tissue microarray validation cohorts included
only 13 % patients with distant metastasis. Thus, the
power to identify genes with prognostic impact may
be limited.
Conclusions
We have identified several novel biomarkers of poten-
tial diagnostic interest. The dopamine transporter
SLC6A3 furthermore seems to be of prognostic inter-




Fresh-frozen tissues from patients undergoing radical or
partial nephrectomy were prospectively collected in the
Biobank at the CIO Cologne Bonn at the University
Hospital Bonn according to standard operating proce-
dures. The renal tissue specimen were snap-frozen, and
a cancerous and a normal sample from each patient was
stored at -80 °C. To confirm the underlying histology,
haematoxylin and eosin stained sections were made forreview by an experienced uropathologist (S.P.). The 7th
edition of the TNM classification from 2009 was applied
for RCC staging. We investigated a discovery cohort
with 15 patients (ccRCC and adjacent normal renal
tissue) to screen mRNA expression using microarray
technology; an independent validation cohort with 52
ccRCC and 51 normal renal tissue samples was used for
PCR experiments. The detailed clinical-pathological
parameters are reported in Table 3. All patients gave
written informed consent for the collection of biomate-
rials. The study was approved by the Ethikkommission
at the Universitätsklinikum Bonn (number: 280/12).
RNA isolation
RNA isolation of tissue samples was described earlier
[28]: Approximately 50 mg tissue was homogenized,
total RNA isolated using the mirVana miRNA Isolation
Kit (Ambion, Foster City, CA, USA) and the RNA
treated twice with DNase (DNA-free Kit, Ambion). The
RNA quantity was measured (NanoDrop 2000 spectro-
photometer; Thermo Scientific, Wilmington, DE, USA).
RNA integrity was analyzed with a RNA 6000 n Kit on
the Bioanalyzer 2100 (Agilent Technologies, Santa Clara,
CA, USA); samples with a RIN > 6 were used for micro-
array experiments. RNA degradation was excluded by
gel electrophoresis in samples used for PCR.
Microarray analysis
The data from the microarray study were reported earl-
ier (Gene Expression Omnibus database: GSE61763,
[29]). In brief, microarray experiments were performed
to determine the expression profile of 34,144 mRNA in
15 corresponding normal and ccRCC tissues. The micro-
array analysis was performed by Biogazelle (Zwijnaarde,
Belgium) as a contract service. Background substracted
and log2-based, normalized expression data were ob-
tained for further data analysis. Based on normalized
expression data, samples were gene wise scaled and
centered, adjusting the inter-sample variance to 1.
Differential expression was calculated pairwise, subtract-
ing corresponding normal tissue from ccRCC tissue
Table 3 Clinical-pathological parameters of patients in the screening and validation cohort
microarray screening cohort PCRvalidation cohort tissue microarray cohort
n = 15 (%) cancern = 52 (%) normaln = 51 (%) n = 134 (%)
Sex
male 10 (66.6) 35 (67.3) 35 (68.6) 85 (63.4)
female 5 (33.3) 17 (32.7) 16 (31.4) 49 (36.6)
Age
mean 61.2 62.5 62.0 62.3
min-max 43-86 36-86 36-86 33-85
Pathological stage
pT1 4 (26.7) 29 (55.8) n.a. 55 (41.0)
pT2 2 (13.3) 5 (9.6) n.a. 30 (22.4)
pT3 9 (60.0) 17 (32.7) n.a. 47 (35.1)
pT4 0 (0) 1 (1.9) n.a. 2 (1.5)
lymph node metastasis 0 (0) 2 (3.8) n.a. 7 (5.2)
distant metastasis 1 (6.7) 7 (13.5) n.a. 17 (12.7)
Fuhrman Grading
grade 1 2 (13.3) 4 (7.7) n.a. 40 (29.9)
grade 2 11 (73.3) 40(76.9) n.a. 91 (67.9)
grade 3 2 (13.3) 7 (13.5 %) n.a. 3 (2.2)
grade 4 0 (0) 1 (1.9) n.a. 0
n.a. not applicable
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ranked with the highest (respectively lowest) differen-
tial expression value where taken into account, fur-
ther p-value of the t-test for these genes had to be
significant (p < 0.05). Clustering and heatmap aggregation,
based on the top 25 up and 25 down ranked genes, was
performed in euclidean space using complete linkage and
gplot’s heatmap.2 function. Color coding was performed
using the RColorBrewer Package. For all analyses R
v3.2.0., with the packages mentioned has been performed.
Real-Time PCR
To validate the microarray results, we investigated the
expression of most differentially regulated mRNAs in an
independent cohort (52 ccRCC and 51 normal renal
tissue samples). cDNA was synthesized with 1 μg RNA
using the PrimeScript RT Reagent Kit with gDNA
Eraser. Real-Time PCR was performed with 5 ng cDNA
template using the 1x SYBR Premix Ex Taq II with ROX
Plus and 10 pmol/μl PCR primers; all reagents were
from Takara Bio, Saint-Germain-en-Laye, France. The
primer sequences are provided in Additional file 1: Table
S1. PCR experiments were performed on an ABIPrism
7900 HT Fast Real-Time PCR System (Applied Biosys-
tems, Foster City, CA, USA). Data were analyzed using
Qbase + (Biogazelle) with ACTB and TBP, earlier shown
to be suitable reference genes [30], in the 2-ΔΔCT
algorithm. Statistical analyses (Mann-Whitney-U test,Cox regression analysis) were performed with SPSS
Statistics v21 (IBM, Ehningen, Germany).
Western blot
Western Blot analyses were performed to determine the
expression of six differentially expressed mRNAs on the
protein level. We investigated eight corresponding
ccRCC and normal renal tissues; the fresh-frozen tissue
samples were located adjacent to the tissue used for
RNA isolation. Approximately 50 mg tissue was homog-
enized in a Precellys 24 (Peqlab, Erlangen, Germany)
with 400 μl Cell Lysis Buffer (Cell Signaling, Cambridge,
United Kingdom) including protease inhibitor (Complete
Mini EDTA-free, Roche, Basel, Switzerland). After de-
termination of the protein concentration (BCA Protein
Assay Kit, Pierce Biotechnology, Rockford, IL, USA),
30 ng protein was loaded per lane into a NuPAGE 3–8 %
or 4–12 % denaturating PAA Gel (Life Technologies,
Carlsbad, CA, USA) and separated in a XCell4 SureLock
electrophoresis system (Life Technologies). A biotinylated
protein ladder (catalog number 7727S, Cell Signaling) was
used as molecular weight marker. After the transfer on
0.2 μm nitrocellulose (XCell II, Life Technologies) and a
5 % milk powder (Merck, Darmstadt, Germany) protein
block, the immunostaining procedure was performed
with antibodies against SLC6A3 (#LS-B7715, LSBio,
Seattle, WA, USA), SLC12A1 (#NBP1-80993, Novus Bio,
Cambridge, United Kingdom), FXYD4 (#NBP1-84489,
Schrödter et al. Molecular Cancer  (2016) 15:10 Page 9 of 10Novus Bio), NPTX2 (#ab115528, Abcam, Cambridge,
United Kingdom), KNG1 (#ab124737, Abcam), NDU-
F4AL2 (#ab190007, Abcam), beta-actin (#A5316, Sigma)
and GAPDH (#2118, Cell Signaling). The detection was
carried out with horseradish peroxidase conjugated to sec-
ondary antibodies (anti-mouse-POD, #170-6516, Biorad,
Munich, Germany; anti-rabbit-POD, #170-6515, Biorad;
anti-biotin-POD, #7075, Cell Signaling). The development
of the chemiluminescent signal was done by SuperSignal
West Femto (Pierce Technology) and documented by the
LAS 3000 Image Reader (Fujifil, Tokyo, Japan).
Immunohistochemistry
A tissue microarray [31] was used to determine the ex-
pression of SLC6A3 in ccRCC (n = 134) and normal renal
tissue samples (n = 21). The expression pattern in the
distal/proximal tubule and Henle’s loop was recorded
separately. Paraffin sections of 5 μm thickness were cut
from the tissue microarray block, and subsequently
stained with an antibody against SLC6A3 (dilution 1:100).
Immunohistochemical staining was performed using the
Ventana Benchmark automated staining system (Ventana
Medical System, Tuscon, AZ, USA). The slides were incu-
bated with the primary antibody for 40 min at room
temperature, whereby antibody dilution was conducted
with the Ventana diluent. Signal detection was performed
with the Ventana DABMap Kit combined with Universal
Secondary Antibody. The slides were finally counter-
stained with haematoxylin and Bluing Reagent, dehy-
drated and mounted.
Each slide was scanned by the Panoramic Midi (3D
HISTECH, Budapest, Hungary). An image analysis soft-
ware (Tissue Studie v2.1; Definiens, Munich, Germany)
was used to obtain a continuous spectrum of average
staining intensity as reported before [32]. The staining
intensities were statistically evaluated using SPSS Statis-
tics v21; the SPSS Mann-Whitney-U test was applied to
compare SLC6A3 expression in normal and tumor
tissues. Kaplan Meier estimates and Cox regression
analyses were performed to determine the relevance of
SLC6A3 expression for progression-free, cancer specific
and overall survival.
SLC6A3 ELISA
We used a commercial enzyme linked immunosorbent
assay (ELISA) kit for SLC6A3 (Human Dopamine
Transporter ELISA Kit, #DL-DAT-Hu; Wuxi Donglin
Sci & Tech Development, Jiangsu, China) to determine
the concentration of circulating SLC6A3 in ccRCC
patients. The ELISA was performed with 100 μl serum
essentially as recommended by the supplier. The optical
density was recorded with a Safire photometer (Tecan,
Männedorf, Switzerland) at 450 nm. Data analysis was
performed with the Magellan Software v7.2. We examined15 healthy individuals and 18 patients with ccRCC (stage
I: n = 10; stage II: n = 3; stage III: n = 3, stage 4: n = 2). All
samples were measured in duplicate.
Cell culture and sertraline treatment
The RCC cell lines Caki-1 and A498 were purchased from
DSMZ (Braunschweig, Germany). Cells were grown in
RPMI 1640 supplemented with 10 % heat-inactivated fetal
calf serum, glutamine (PAA, Pasching, Austria) and 1 %
penicillin/streptomycin (Invitrogen, Paisley, Scotland) and
incubated at 37 °C, 5 % CO2. The cell lines were treated
with 0 μM, 12.5 μM, 25 μM and 50 μM sertraline
(SLC6A3 inhibitor) for up to 72 h in six replicates in
96-well tissue culture plates, which contained 1.5x104
cells/well. Cells were cultured up to 72 h to assess
cell viability using the EZ4U test.
Additional file
Additional file 1: List of qPCR primer sequences used for the
validation study. (PDF 811 kb)
Competing interests
The authors disclose any conflict of interest.
Authors’ contributions
S.S. and J.E. conceived and designed the experiments. S.S., M.B., N.K., I.S. and
D.S. performed the experiments. S.S. and J.E. analyzed the data. M.D.
performed bioinformatic analyses. S.S., M.B. and J.E. wrote the manuscript.
S.P. and S.C.M. contributed reagents, material and analytical tools. All authors
have read and approved the final manuscript.
Acknowledgements
The tissue samples were collected within the framework of the Biobank of
the Center for Integrated Oncology Cologne Bonn at the University Hospital
Bonn. We thank Elena Perabo for technical assistance. Isabella Syring is
supported by a grant of the Ferdinand Eisenberger Foundation of the
German Association of Urology. Sven Perner is supported by a grant of the
Rudolf Becker Foundation.
Author details
1Department of Urology, University Hospital Bonn, Bonn, Germany. 2Section
for Prostate Cancer Research, Institute of Pathology, Center for Integrated
Oncology, University Hospital Bonn, Cologne/Bonn, Germany. 3Klinik und
Poliklinik für Urologie und Kinderurologie, Universitätsklinikum Bonn,
Sigmund-Freud-Strasse 25, 53105 Bonn, Germany.
Received: 5 August 2015 Accepted: 27 January 2016
References
1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW,
Comber H, et al. Cancer incidence and mortality patterns in Europe:
estimates for 40 countries in 2012. European journal of cancer (Oxford,
England : 1990). 2013;49(6):1374-403. Epub 2013/03/15. doi: 10.1016/j.
ejca.2012.12.027. PubMed
2. King SC, Pollack LA, Li J, King JB, Master VA. Continued Increase in Incidence
of Renal Cell Carcinoma, Especially in Young Patients and High Grade
Disease: United States 2001 to 2010. J Urol. 2014. Epub 2014/01/16.
doi: 10.1016/j.juro.2013.12.046. PubMed
3. La Rochelle J, Wood C, Bex A. Refining the use of cytoreductive
nephrectomy in metastatic renal cell carcinoma. Semin Oncol. 2013;40(4):
429–35. doi:10.1053/j.seminoncol.2013.05.007. Epub 2013/08/27. PubMed.
4. Albiges L, Choueiri T, Escudier B, Galsky M, George D, Hofmann F, et al. A
systematic review of sequencing and combinations of systemic therapy in
metastatic renal cancer. Eur Urol. 2014. doi:10.1016/j.eururo.2014.04.006.
Epub 2014/05/21. PubMed.
5. Croft D, Mundo AF, Haw R, Milacic M, Weiser J, Wu G, et al. The Reactome
pathway knowledgebase. Nucleic acids research. 2014;42(Database issue):
D472-7. Epub 2013/11/19. doi: 10.1093/nar/gkt1102. PubMed PMID:
24243840; PubMed Central PMCID: PMCPmc3965010.
6. Kupershmidt I, Su QJ, Grewal A, Sundaresh S, Halperin I, Flynn J, et al.
Ontology-based meta-analysis of global collections of high-throughput
public data. PloS one. 2010;5(9). Epub 2010/10/12. doi: 10.1371/journal.pone.
0013066. PubMed PMID: 20927376; PubMed Central PMCID:
PMCPmc2947508.
7. Comprehensive molecular characterization of clear cell renal cell carcinoma.
Nature. 2013;499(7456):43-9. Epub 2013/06/25. doi: 10.1038/nature12222.
PubMed PMID: 23792563; PubMed Central PMCID: PMCPmc3771322.
8. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio
cancer genomics portal: an open platform for exploring multidimensional
cancer genomics data. Cancer discovery. 2012;2(5):401-4. Epub 2012/05/17.
doi: 10.1158/2159-8290.cd-12-0095. PubMed PMID: 22588877; PubMed
Central PMCID: PMCPmc3956037.
9. Pena-Llopis S, Vega-Rubin-de-Celis S, Liao A, Leng N, Pavia-Jimenez A, Wang
S, et al. BAP1 loss defines a new class of renal cell carcinoma. Nature
genetics. 2012;44(7):751-9. Epub 2012/06/12. doi: 10.1038/ng.2323. PubMed
PMID: 22683710; PubMed Central PMCID: PMCPmc3788680.
10. Wang Y, Roche O, Yan MS, Finak G, Evans AJ, Metcalf JL, et al. Regulation of
endocytosis via the oxygen-sensing pathway. Nat Med. 2009;15(3):319–24.
doi:10.1038/nm.1922. Epub 2009/03/03. PubMed.
11. Ooi A, Wong JC, Petillo D, Roossien D, Perrier-Trudova V, Whitten D, et al. An
antioxidant response phenotype shared between hereditary and sporadic type
2 papillary renal cell carcinoma. Cancer Cell. 2011;20(4):511–23. doi:10.1016/j.
ccr.2011.08.024. Epub 2011/10/22. PubMed.
12. Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, Varela I, et al.
Genomic architecture and evolution of clear cell renal cell carcinomas
defined by multiregion sequencing. Nat Genet. 2014;46(3):225–33. doi:10.
1038/ng.2891. Epub 2014/02/04. PubMed.
13. Tian Q, Stepaniants SB, Mao M, Weng L, Feetham MC, Doyle MJ, et al.
Integrated genomic and proteomic analyses of gene expression in
Mammalian cells. Mol Cell Proteomics. 2004;3(10):960–9. doi:10.1074/mcp.
M400055-MCP200. Epub 2004/07/09. PubMed.
14. Pascal LE, True LD, Campbell DS, Deutsch EW, Risk M, Coleman IM, et al.
Correlation of mRNA and protein levels: cell type-specific gene expression
of cluster designation antigens in the prostate. BMC genomics. 2008;9:246.
Epub 2008/05/27. doi: 10.1186/1471-2164-9-246. PubMed PMID: 18501003;
PubMed Central PMCID: PMCPmc2413246.
15. Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T, et al.
Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet.
2013;45(8):860–7. doi:10.1038/ng.2699. Epub 2013/06/26. PubMed.
16. Seyednasrollah F, Rantanen K, Jaakkola P, Elo LL. ROTS: reproducible RNA-
seq biomarker detector-prognostic markers for clear cell renal cell cancer.
Nucleic Acids Res. 2015. doi:10.1093/nar/gkv806. Epub 2015/08/13. PubMed.
17. Chen S, Xuan J, Wan L, Lin H, Couch L, Mei N, et al. Sertraline, an
antidepressant, induces apoptosis in hepatic cells through the mitogen-
activated protein kinase pathway. Toxicol Sci. 2014;137(2):404–15. doi:10.
1093/toxsci/kft254. Epub 2013/11/07. PubMed.
18. Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of
antidepressants and related compounds at human monoamine transporters.
Eur J Pharmacol. 1997;340(2-3):249–58. Epub 1998/04/16. PubMed.
19. Krause J. SPECT and PET of the dopamine transporter in attention-deficit/
hyperactivity disorder. Expert Rev Neurother. 2008;8(4):611–25. doi:10.1586/
14737175.8.4.611. Epub 2008/04/18. PubMed.
20. von Roemeling CA, Radisky DC, Marlow LA, Cooper SJ, Grebe SK, Anastasiadis
PZ, et al. Neuronal pentraxin 2 supports clear cell renal cell carcinoma by
activating the AMPA-selective glutamate receptor-4. Cancer research. 2014;
74(17):4796-810. Epub 2014/06/26. doi: 10.1158/0008-5472.can-14-0210.
PubMed PMID: 24962026; PubMed Central PMCID: PMCPmc4154999.
21. Zhang L, Gao J, Li Z, Gong Y. Neuronal pentraxin II (NPTX2) is frequently
down-regulated by promoter hypermethylation in pancreatic cancers. Dig
Dis Sci. 2012;57(10):2608–14. doi:10.1007/s10620-012-2202-8. Epub 2012/07/
19. PubMed.
22. Sweadner KJ, Arystarkhova E, Donnet C, Wetzel RK. FXYD proteins as
regulators of the Na, K-ATPase in the kidney. Ann N Y Acad Sci. 2003;986:
382–7. Epub 2003/05/24. PubMed.
23. Liu H, Brannon AR, Reddy AR, Alexe G, Seiler MW, Arreola A, et al.
Identifying mRNA targets of microRNA dysregulated in cancer: with
application to clear cell Renal Cell Carcinoma. BMC systems biology. 2010;4:
51. Epub 2010/04/28. doi: 10.1186/1752-0509-4-51. PubMed PMID:
20420713; PubMed Central PMCID: PMCPmc2876063.
24. Januchowski R, Zawierucha P, Andrzejewska M, Rucinski M, Zabel M.
Microarray-based detection and expression analysis of ABC and SLC
transporters in drug-resistant ovarian cancer cell lines. Biomedicine &
pharmacotherapy = Biomedecine & pharmacotherapie. 2013;67(3):240-5.
Epub 2013/03/07. doi: 10.1016/j.biopha.2012.11.011. PubMed
25. Phipps JA, Feener EP. The kallikrein-kinin system in diabetic retinopathy:
lessons for the kidney. Kidney Int. 2008;73(10):1114–9. doi:10.1038/ki.2008.9.
Epub 2008/02/15. PubMed.
26. Song JS, Sainz IM, Cosenza SC, Isordia-Salas I, Bior A, Bradford HN, et al.
Inhibition of tumor angiogenesis in vivo by a monoclonal antibody
targeted to domain 5 of high molecular weight kininogen. Blood. 2004;
104(7):2065–72. doi:10.1182/blood-2004-02-0449. Epub 2004/05/27. PubMed.
27. He X, Wang Y, Zhang W, Li H, Luo R, Zhou Y, et al. Screening differential
expression of serum proteins in AFP-negative HBV-related hepatocellular
carcinoma using iTRAQ -MALDI-MS/MS. Neoplasma. 2014;61(1):17–26. Epub
2013/11/08. PubMed.
28. Blondeau JJ, Deng M, Syring I, Schrodter S, Schmidt D, Perner S, et al.
Identification of novel long non-coding RNAs in clear cell renal cell
carcinoma. Clin Epigenetics. 2015;7(1):10. Epub 2015/02/17. doi: 10.1186/
s13148-015-0047-7. PubMed PMID: 25685243; PubMed Central PMCID:
PMCPmc4326488.
29. Deng M, Blondeau JJ, Schmidt D, Perner S, Muller SC, Ellinger J.
Identification of novel differentially expressed lncRNA and mRNA transcripts
in clear cell renal cell carcinoma by expression profiling. Genomics data.
2015;5:173-5. Epub 2015/10/21. doi: 10.1016/j.gdata.2015.06.016. PubMed
PMID: 26484251; PubMed Central PMCID: PMCPmc4584005.
30. Jung M, Ramankulov A, Roigas J, Johannsen M, Ringsdorf M, Kristiansen G,
et al. In search of suitable reference genes for gene expression studies of
human renal cell carcinoma by real-time PCR. BMC molecular biology. 2007;
8:47. Epub 2007/06/15. doi: 10.1186/1471-2199-8-47. PubMed PMID:
17559644; PubMed Central PMCID: PMCPmc1913536.
31. Ellinger J, Kahl P, Mertens C, Rogenhofer S, Hauser S, Hartmann W, et al.
Prognostic relevance of global histone H3 lysine 4 (H3K4) methylation in
renal cell carcinoma. Int J Cancer. 2010;127(10):2360–6. doi:10.1002/ijc.25250.
Epub 2010/02/18. PubMed.
32. Braun M, Kirsten R, Rupp NJ, Moch H, Fend F, Wernert N, et al.
Quantification of protein expression in cells and cellular
subcompartments on immunohistochemical sections using a computer
supported image analysis system. Histol Histopathol. 2013;28(5):605–10.
Epub 2013/01/31. PubMed.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Schrödter et al. Molecular Cancer  (2016) 15:10 Page 10 of 10
